Bristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59 - BMY News | RalliesBristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59
B
BMY• Quarterly results and outlook
- Bristol-Myers Squibb Co reported Q2 adjusted EPS of $2.04, versus the IBES estimate of $1.59.
- Q2 revenue was $12.97 billion, versus the IBES estimate of $11.75 billion.
- The company said FY adjusted EPS is expected to be $6.75 to $7.00, versus the IBES estimate of $6.34.
- Bristol Myers said FY Eliquis revenue growth is expected to be 20%–25%, versus a prior forecast of 10%–15%.
•
